Size Exclusion Analysis of Avastin and Erbitux on Zenix® SEC-300

Size Exclusion Analysis of Avastin and Erbitux on Zenix® SEC-300

Conditions

column Zenix SEC-300, 30 cm x 7.8 mm I.D., 3 µm particles, 300 Ã… (Z777033)
column temp. 25 °C
mobile phase 150 mM phosphate buffer, pH 7.0
flow rate 1.0 mL/min
sample (top) Bevacizumab (trade name Avastin), a humanized monoclonal antibody(bottom) Cetuximab (trade name Erbitux), a chimeric monoclonal antibody
injection 10 µL
detector UV, 280 nm

Description

Analysis Note The quality control analysis of recombinant monoclonal antibody therapeutics by gel filtration chromatography is a standard release test to determine antibody purity and the level of aggregation. Bevacizumab, sold under the trade name Avastin, is a humanized monoclonal antibody used in the treatment of colorectal, breat and lung cancer. Similarly, cetuximab, sold under the trade name Erbitux, is a chimeric monoclonal antibody used in the treatment of metastatic colorectal cancer. Both mAbs have molecular masses of about 150 kD.
Categories Analytical Chromatography, Antibodies
Featured Industry Life Science and Biopharma
Legal Information Zenix is a registered trademark of Sepax Technologies
suitability application for HPLC

Materials

     
Related Links